Leg Pain & Sciatica Treatment in Birmingham & Bessemer, AL

Leg Pain & Sciatica Treatment at Alabama Pain Physicians

Sciatica and leg pain can range from a mild ache to debilitating shooting pain that makes it impossible to walk, sit, or sleep. Our physicians see these patients every day and have effective treatments that work.

Your treatment plan may include:

• Medical management — nerve stabilizers (gabapentin, pregabalin), anti-inflammatories, and targeted medications for neuropathic pain
• Epidural steroid injections — delivered precisely to the compressed nerve root causing your leg pain
• Transforaminal epidurals — targeted injections at the specific nerve foramen where compression occurs
• Peripheral nerve blocks — for leg pain caused by specific nerve entrapment
• Radiofrequency ablation — long-lasting pain relief by interrupting nerve pain signals
• Spinal cord stimulation — for chronic sciatica that hasn't responded to conservative treatment
• Medical marijuana certification — for qualifying patients with chronic nerve pain

Leg pain has many causes — not all leg pain is sciatica. We perform a comprehensive evaluation to find exactly what's causing your pain and treat it at the source.

Understanding Leg Pain: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind why leg pain develops and persists. This research informs how we approach complex and treatment-resistant cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed thousands of patients with chronic pain conditions including radiculopathy, peripheral neuropathy, vascular claudication, and chronic venous insufficiency. The consistent observation that drives this publication series is the limited, partial treatment response that characterizes conventional management of chronic leg pain across all modalities. Gabapentin reduces neuropathic leg pain by fifty percent in roughly one out of six patients. Epidural steroid injections provide weeks of relief for radicular pain, then the pain returns. Cilostazol adds approximately forty meters to walking distance in patients with vascular claudication. These partial responses are not clinical failures in the traditional sense — each intervention does what it is designed to do. They are evidence that the interventions are addressing only one component of a multi-component problem.

This observation led me to cellular systems biology as a framework for understanding the clinical entities I encounter daily. Leg pain is particularly instructive because it presents through at least five distinct mechanisms — radiculopathy, peripheral neuropathy, vascular claudication, chronic venous insufficiency, and neurogenic claudication — that conventional medicine treats as unrelated diagnoses requiring separate specialists. Cellular systems theory proposes that these apparently distinct presentations share upstream biological drivers in the metabolic, inflammatory, vascular, and neuroendocrine domains. I have spent years developing assessment protocols, building laboratory infrastructure through CLIA-certified laboratories, and studying the biological pathways that connect these domains. I own clinics, laboratories, and value-based care companies with the goal of providing patients better outcomes.

These publications are my attempt to provide information about this understanding — how common clinical manifestations of pain can be explained, diagnosed, and treated through cellular systems analysis. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Leg pain affects millions of Americans through multiple pathological mechanisms including lumbar radiculopathy (lifetime prevalence 13–40%; Konstantinou and Dunn, Spine, 2008), peripheral neuropathy (prevalence 3.2–10.3% in the general population; Bouhassira, Revue Neurologique, 2019), peripheral artery disease (affecting over 200 million people worldwide; Criqui et al., Circulation, 2021), chronic venous insufficiency (approximately 25 million Americans with varicose veins and up to 6 million with advanced disease; Eberhardt and Raffetto, Circulation, 2014), and neurogenic claudication from lumbar spinal stenosis. Current treatment approaches target individual mechanisms: gabapentinoids modulate calcium channel subunit activity for neuropathic pain (NNT 5.9 for diabetic neuropathy; Wiffen et al., Cochrane Database of Systematic Reviews, 2017), epidural steroid injections suppress perineural inflammation (NNT 4 short-term; AAN, Neurology, 2025), and cilostazol provides modest improvement in claudication walking distance (approximately 40 meters over placebo; Brown et al., Cochrane Database of Systematic Reviews, 2021). These limited response rates suggest that single-pathway interventions are insufficient for conditions involving multiple biological systems.

Methods

We conducted a narrative review of PubMed-indexed literature examining leg pain through cellular systems theory, which proposes that chronic leg pain emerges from dynamic interactions across seven biological domains. We reviewed evidence for metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural domain involvement in radiculopathy, peripheral neuropathy, vascular claudication, chronic venous insufficiency, and neurogenic claudication. We analyzed treatment response data for conventional interventions and constructed composite clinical scenarios illustrating individualized multi-domain assessment and intervention.

Results

Published evidence demonstrates that leg pain involves dysfunction across multiple biological domains: insulin resistance is independently associated with low back pain and radiculopathy (Que et al., Frontiers in Medicine, 2025); metabolic syndrome doubles the risk of peripheral artery disease (Garg et al., Hypertension, 2014); TNF-α is required for nerve root compression to produce radicular symptoms (Olmarker et al., Spine, 1993); altered gut microbiome composition correlates with pain severity (Minerbi et al., Pain, 2019); and the concept of metabolic nerve vulnerability explains why structurally identical nerve compressions produce different clinical outcomes depending on the metabolic environment surrounding the nerve.

Conclusions

The pattern of multi-domain biological dysfunction combined with limited, partial response to single-pathway treatments supports the hypothesis that chronic leg pain represents a multi-system cellular disorder requiring individualized, domain-specific intervention. Cellular systems theory provides a framework for identifying which domains are dysfunctional in each patient and directing treatment accordingly. Emerging peptide therapeutics including ARA-290 (cibinetide), which has demonstrated nerve fiber regeneration in Phase II clinical trials for small fiber neuropathy, offer potential for domain-targeted intervention.

1. Introduction

Leg pain is among the most common complaints in clinical medicine, yet it encompasses pathologies that span neurology, vascular surgery, interventional pain management, and primary care. A patient presenting with leg pain may have lumbar radiculopathy from a herniated disc, diabetic peripheral neuropathy, vascular claudication from peripheral artery disease, chronic venous insufficiency, neurogenic claudication from spinal stenosis, or — frequently — more than one of these simultaneously. The lifetime prevalence of sciatica alone is estimated at 13–40% (Konstantinou and Dunn, Spine, 2008). Peripheral artery disease affects over 200 million people worldwide (Criqui et al., Circulation, 2021). Neuropathic pain has a general population prevalence of 3.2–10.3%, with rates as high as 23–46.5% in patients with diabetic neuropathy (Bouhassira, Revue Neurologique, 2019).

The prevailing clinical model treats each leg pain diagnosis as a discrete entity requiring a specific intervention. Radiculopathy receives epidural injections or surgery. Neuropathy receives gabapentinoids or duloxetine. Claudication receives cilostazol or revascularization. Venous insufficiency receives compression or ablation. This model is logical, evidence-based for acute intervention, and frequently effective in the short term. However, the long-term clinical performance of these single-pathway approaches challenges their sufficiency.

Musculoskeletal conditions — including piriformis syndrome, hip-referred pain, iliotibial band syndrome, myofascial trigger points, and lower extremity tendinopathy — also produce leg pain and are routinely evaluated in clinical practice. These conditions are important diagnostic considerations and are addressed through targeted musculoskeletal examination. This publication focuses on the five categories of leg pain where multi-domain biological dysfunction is most clearly documented in the published literature and where conventional single-pathway treatment response is most limited: radiculopathy, peripheral neuropathy, vascular claudication, chronic venous insufficiency, and neurogenic claudication. Musculoskeletal conditions of the hip, knee, and lower extremity are addressed in companion publications in this series.

The concept of metabolic nerve vulnerability is central to understanding why conventional approaches produce limited results. A nerve compressed by a disc herniation in a patient with normal metabolic function may recover spontaneously — indeed, the natural history of sciatica is generally favorable, with the greatest improvement occurring within the initial three months (Peul et al., New England Journal of Medicine, 2007). But the same degree of compression in a patient with insulin resistance, microvascular dysfunction, and systemic inflammation may produce severe, persistent radiculopathy. The nerve itself is metabolically vulnerable — its vasa nervorum are compromised, its energy supply is impaired, its inflammatory environment is hostile. The structural finding is the same. The biological context determines the clinical outcome.

Cellular systems theory proposes that leg pain — whether radicular, neuropathic, vascular, or venous — emerges from the interaction of metabolic, inflammatory, vascular, hormonal, and structural domains that conventional medicine evaluates in isolation. The disc, the nerve, the artery, and the vein do not degenerate in biological isolation. They degenerate within a shared metabolic and inflammatory environment that either supports or undermines their integrity and repair. When that environment is dysfunctional across multiple domains simultaneously, single-pathway interventions cannot produce sustained improvement because the biological conditions that caused the damage remain active.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining biological domain dysfunction in chronic leg pain. Search terms included leg pain, sciatica, radiculopathy, peripheral neuropathy, diabetic neuropathy, small fiber neuropathy, peripheral artery disease, claudication, chronic venous insufficiency, and neurogenic claudication combined with insulin resistance, metabolic syndrome, inflammation, NF-κB, cytokines, HPA axis, cortisol, microbiome, oxidative stress, mitochondrial dysfunction, endothelial dysfunction, microvascular, vasa nervorum, and treatment response. We included systematic reviews, meta-analyses, randomized controlled trials, and large population-based cohort studies published in English-language peer-reviewed journals. We analyzed treatment response data from systematic reviews and meta-analyses of conventional leg pain interventions. We constructed composite clinical scenarios to illustrate individualized multi-domain assessment and intervention.

3. The Limitations of Single-Pathway Treatment

3.1 Pharmacological Interventions for Neuropathic Leg Pain

Gabapentin, the most widely prescribed agent for neuropathic pain, has a number needed to treat (NNT) of 5.9 for at least fifty percent pain reduction in painful diabetic neuropathy and an NNT of 8.0 for postherpetic neuralgia at doses of 1200 mg or more daily, based on a Cochrane review of 37 studies with 5,914 participants (Wiffen et al., Cochrane Database of Systematic Reviews, 2017). Approximately three to four out of ten participants achieved meaningful pain relief with gabapentin, compared with one to two out of ten with placebo. Over half of patients treated with gabapentin will not have worthwhile pain relief but may experience adverse events including dizziness (NNH 8), somnolence (NNH 11), and peripheral edema (NNH 21). Pregabalin at 600 mg daily has an NNT of 5.0 for painful diabetic neuropathy and 3.9 for postherpetic neuralgia (Derry et al., Cochrane Database of Systematic Reviews, 2019). However, pregabalin causes weight gain that worsens insulin resistance — the metabolic condition driving many patients’ neuropathy — creating a therapeutic contradiction in which the treatment for the symptom accelerates the underlying disease.

Duloxetine at 60 mg daily has an NNT of 5.8 for painful diabetic neuropathy (Sultan et al., Pain, 2008). Gastrointestinal adverse effects including nausea, reported in approximately 25% of patients, may worsen gut barrier function in patients with active microbiome domain dysfunction. Tricyclic antidepressants provide comparable efficacy (NNT approximately 3.5 for combined neuropathic pain; Sindrup and Jensen, Pain, 1999) but are limited by anticholinergic effects, cardiac conduction risk, and sedation that impairs physical activity — itself a critical intervention for metabolic health.

The pharmacotherapy evidence for neuropathic pain as a whole reveals a consistent pattern: NNTs between 4 and 10, meaning that only 10–25% of patients achieve meaningful pain relief beyond placebo (Finnerup et al., Lancet Neurology, 2015). No single agent addresses the metabolic, vascular, inflammatory, or hormonal domains contributing to nerve damage.

3.2 Interventional Procedures for Radiculopathy

Epidural steroid injections for lumbar radiculopathy probably reduce short-term pain with an NNT of 4 and a success rate difference of 24%, according to the 2025 AAN systematic review of 90 randomized controlled trials (AAN Guidelines, Neurology, 2025). However, evidence for long-term pain reduction is insufficient. A meta-analysis of 29 RCTs found that the long-term benefit of epidural steroid injections was not supported after baseline adjustment, and injections did not reduce subsequent surgery rates compared with placebo (Bicket et al., Anesthesiology, 2013). Epidural injections target local perineural inflammation at one spinal level without addressing the systemic metabolic and inflammatory environment that produced the disc degeneration or the metabolic vulnerability of the nerve root itself.

Discectomy for sciatica provides rapid improvement in leg pain and disability compared with conservative treatment, but the benefits decline over time. A systematic review and meta-analysis found very low to low certainty evidence that discectomy was superior in the short term, with diminishing advantage at longer follow-up (Liu et al., BMJ, 2023). Approximately 45% of patients with sciatica managed conservatively in primary care still report chronic symptoms at one-year follow-up (Chiarotto et al., European Journal of Pain, 2020). The structural intervention corrects the mechanical compression without modifying the biology that created the conditions for disc failure and nerve vulnerability.

3.3 Vascular Interventions for Claudication

Cilostazol, the only FDA-approved medication recommended by clinical practice guidelines for intermittent claudication, improves maximal treadmill walking distance by approximately 40 meters over placebo (Brown et al., Cochrane Database of Systematic Reviews, 2021). Side effects leading to discontinuation occur in approximately 20% of patients, including headache (NNH 7), diarrhea, and palpitations. Supervised exercise therapy improves maximal walking distance by approximately 180 meters — substantially more than any pharmacological intervention (Fakhry et al., JAMA, 2012). Endovascular revascularization provides rapid improvement but does not address the atherosclerotic process, the endothelial dysfunction, or the metabolic syndrome driving disease progression. Metabolic syndrome doubles the risk of developing peripheral artery disease (Garg et al., Hypertension, 2014), yet metabolic optimization is rarely included in PAD treatment protocols.

3.4 Synthesis: The Pattern of Partial Response

The treatment response data across all conventional modalities for leg pain converge on a consistent pattern: each intervention provides limited, often short-term benefit to a minority of patients. Gabapentinoids help roughly one in six patients with neuropathic pain. ESIs provide short-term but not durable relief for radiculopathy. Cilostazol adds modest walking distance for claudication. Discectomy benefits decline over time. This is the pattern predicted by a multi-domain disorder being treated with single-domain interventions. If chronic leg pain involves variable dysfunction across metabolic, inflammatory, hormonal, vascular, microbiome, and structural domains, and each patient’s pain reflects a unique combination of domain dysfunction, then a single-mechanism agent would be expected to help only the subset of patients in whom that mechanism is the dominant driver. The limited response rates are not evidence that the interventions are ineffective — they are evidence that the interventions are incomplete.

4. Evidence for Multi-Domain Dysfunction in Leg Pain

4.1 Mitochondrial Function and Metabolic Dysfunction

Insulin resistance damages peripheral nerves through multiple converging pathways, creating the concept of metabolic nerve vulnerability. Chronically elevated blood sugar produces advanced glycation end products (AGEs) — compounds that cross-link proteins in the nerve and its supporting structures, stiffening the endoneurium and impairing nutrient diffusion. Insulin resistance promotes NF-κB activation, a protein complex that functions as a master switch for inflammatory gene activation, driving production of inflammatory cytokines within the nerve itself (Niederberger and Geisslinger, FASEB Journal, 2008). The vasa nervorum — the tiny blood vessels that supply oxygen and nutrients to the nerve — are among the first vascular beds damaged by metabolic syndrome. Endothelial dysfunction in the vasa nervorum reduces nerve perfusion, creating a state of chronic nerve ischemia that makes the nerve vulnerable to any additional insult, including mild mechanical compression that would otherwise be tolerated.

Insulin resistance is independently associated with increased risk of low back pain and radiculopathy in a cross-sectional study of 6,126 US adults (Que et al., Frontiers in Medicine, 2025). A Mendelian randomization study found that metabolic factors may affect intervertebral disc degeneration more than mechanical factors (Guo et al., Spine Journal, 2024). Metabolic syndrome doubles the risk of peripheral artery disease (Garg et al., Hypertension, 2014), directly connecting the metabolic domain to vascular leg pain. The relationship between pain and insulin resistance is bidirectional: animal models demonstrate that chronic pain downregulates insulin receptors in skeletal muscle and spinal cord, accelerating progression to metabolic dysfunction (Zhai et al., Journal of Pain, 2016). This means that untreated leg pain of any cause can worsen the metabolic environment, creating a self-amplifying cascade.

4.2 Immune Surveillance and Inflammation

Inflammatory mediators are required for nerve root compression to produce radicular symptoms. Olmarker et al. demonstrated that application of nucleus pulposus material to a nerve root without mechanical compression produces inflammatory changes and pain behavior, while compression without inflammatory mediators produces significantly less nociceptive response (Olmarker et al., Spine, 1993). This finding has profound implications for leg pain: it means that the inflammatory environment surrounding the nerve root determines whether a given degree of disc pathology becomes symptomatic. Two patients with identical L5-S1 herniations can present with dramatically different clinical pictures because their inflammatory environments differ.

Central sensitization — a state of neural hyperexcitability in which the spinal cord amplifies pain signals and lowers pain thresholds — contributes to chronic leg pain through spinal cord glial cell activation (Woolf, Pain, 2011; Watkins and Maier, Physiological Reviews, 2002). Immune cells including activated microglia release proinflammatory cytokines that enhance synaptic transmission in pain pathways. Systemic inflammation from any source — metabolic, gut-derived, or adipose-driven — feeds this spinal sensitization, explaining why a patient with moderate structural pathology can experience severe and widespread leg symptoms.

4.3 Vascular Integrity

The vascular domain is uniquely central to leg pain because every category of leg pain involves vascular pathology. Radiculopathy involves compromise of the vascular supply to the nerve root. Peripheral neuropathy involves damage to the vasa nervorum. Vascular claudication is directly caused by arterial insufficiency. Chronic venous insufficiency involves venous hypertension and microcirculatory dysfunction. Neurogenic claudication involves vascular congestion within the stenotic spinal canal.

Endothelial dysfunction — impairment of the blood vessel lining that regulates blood flow, inflammation, and nutrient exchange — is the common vascular pathology connecting these conditions. Insulin resistance, chronic inflammation, smoking, and aging all promote endothelial dysfunction through reduced nitric oxide bioavailability. Peripheral artery disease affects over 200 million people worldwide (Criqui et al., Circulation, 2021), yet it is frequently underdiagnosed in patients presenting to pain clinics with leg symptoms. Chronic venous insufficiency remains overlooked by pain physicians as a contributor to leg pain and may coexist with other pain-generating pathologies (Lin et al., World Journal of Clinical Cases, 2024).

4.4 Neuroendocrine Regulation

Sleep disruption independently predicts the transition from acute to chronic pain and the development of widespread pain conditions (Finan et al., Journal of Pain, 2013). Poor sleep quality is bidirectionally linked to pain: sleep disruption amplifies pain, and pain disrupts sleep, creating a self-reinforcing cycle (Choy, Nature Reviews Rheumatology, 2015). Growth hormone, released primarily during deep delta sleep, is essential for nerve repair, collagen synthesis, and tissue maintenance. Chronic sleep disruption reduces growth hormone release, impairing the body’s primary repair window for damaged nerves and vascular structures.

HPA axis dysregulation — the body’s central stress response system — affects nerve repair and inflammatory regulation. Sustained cortisol elevation from chronic stress promotes inflammatory disinhibition and impairs tissue repair (Heim et al., Psychoneuroendocrinology, 2000). Hormonal insufficiency, including testosterone deficiency in both men and women, reduces the anabolic capacity needed for nerve and vascular tissue maintenance.

4.5 Microbiome and Mucosal Immunity

Gut barrier dysfunction allows bacterial lipopolysaccharide (LPS) to translocate into systemic circulation, activating NF-κB-mediated inflammatory cascades that contribute to both neuropathic and vascular pathology (Camilleri, Gut, 2019). Altered gut microbiome composition has been demonstrated in chronic pain populations, with specific bacterial taxa correlating with pain severity (Minerbi et al., Pain, 2019). Small intestinal bacterial overgrowth has been associated with chronic pain syndromes (Erdrich et al., Clinical and Experimental Rheumatology, 2020). Gut-derived systemic inflammation feeds the same inflammatory tone that sensitizes nerve roots, damages the vasa nervorum, and accelerates atherosclerotic disease in the lower extremities.

4.6 Detoxification and Oxidative Stress

Oxidative stress damages nerve cells through reactive oxygen species (ROS) that overwhelm antioxidant defenses. Environmental toxic burden including heavy metals — particularly mercury and lead — directly damages peripheral nerves through neurotoxic mechanisms. Mercury disrupts mitochondrial function in Schwann cells, the cells responsible for myelin maintenance in peripheral nerves. Glutathione, the body’s master antioxidant and primary Phase II detoxification molecule, is often depleted in patients with chronic metabolic stress, reducing both antioxidant protection and the clearance of inflammatory mediators.

4.7 Structural Domain: The Metabolically Vulnerable Nerve

Small fiber neuropathy — damage to the small unmyelinated C-fibers and thinly myelinated A-delta fibers responsible for pain and temperature sensation — has been documented through skin biopsy showing reduced intraepidermal nerve fiber density in patients with chronic pain conditions (Uceyler et al., Brain, 2013). This provides objective structural evidence of peripheral nerve damage that conventional calcium-channel modulators and serotonin-norepinephrine reuptake inhibitors do not address. Microvascular pathology in the form of excessive peptidergic sensory innervation of cutaneous arteriole-venule shunts has been demonstrated in chronic pain patients, providing a peripheral vascular mechanism for pain and temperature sensitivity (Albrecht et al., Pain Medicine, 2013).

The intervertebral disc, discussed extensively in the companion low back pain publication (Thomas, Alabama Pain Physicians, 2026), is the largest avascular structure in the body. Disc degeneration is nearly universal in the asymptomatic population — 37% at age 20 and 96% at age 80 (Brinjikji et al., AJNR, 2015) — demonstrating that structural degeneration alone is insufficient to explain who develops radicular leg pain and who does not. The structural domain in cellular systems theory represents the visible downstream consequence of upstream dysfunction across the metabolic, inflammatory, hormonal, vascular, and mitochondrial domains.

5. Inter-Domain Cascade Mechanics

5.1 The Metabolic Nerve Vulnerability Cascade

Insulin resistance (Que et al., 2025) damages the vasa nervorum through endothelial dysfunction, reducing nerve perfusion and creating chronic nerve ischemia. Simultaneously, AGE accumulation stiffens the endoneurium and impairs nutrient diffusion within the nerve. NF-κB activation (Niederberger and Geisslinger, 2008) drives intraneural inflammation. The result is a metabolically vulnerable nerve — one that cannot tolerate mechanical stress, ischemia, or inflammatory insult that a healthy nerve would easily withstand. When this metabolically vulnerable nerve encounters even mild disc protrusion or foraminal narrowing, it becomes symptomatic. The epidural injection suppresses the perineural inflammation temporarily but cannot reverse the vasa nervorum damage, the AGE accumulation, or the intraneural metabolic dysfunction. This explains why many patients with radiculopathy experience temporary relief followed by recurrence: the structural intervention addresses the local inflammation without modifying the biology that made the nerve vulnerable.

5.2 The Vascular-Metabolic-Inflammatory Cascade in PAD

Metabolic syndrome (which doubles PAD risk; Garg et al., 2014) promotes atherosclerotic plaque formation through multiple pathways: insulin resistance drives endothelial dysfunction, dyslipidemia accelerates lipid deposition, and chronic hyperglycemia promotes glycation of arterial wall proteins. Visceral adipose tissue produces TNF-α and IL-6 that activate NF-κB signaling in the arterial wall, promoting plaque instability and inflammation. Reduced physical activity from claudication symptoms worsens insulin resistance, reduces mitochondrial density in skeletal muscle, and eliminates the anti-inflammatory effects of exercise including endogenous MOTS-c production (Lee et al., Cell Metabolism, 2015). Cilostazol provides a modest vasodilatory effect without addressing the metabolic syndrome, endothelial dysfunction, or inflammatory environment driving disease progression.

5.3 The Sleep-Hormone-Repair Cascade

Sleep disruption (Finan et al., 2013; Choy, 2015) reduces deep sleep-dependent growth hormone release, impairing nerve repair and vascular endothelial maintenance. HPA axis dysregulation from chronic pain-related stress produces cortisol abnormalities that impair tissue repair (Heim et al., 2000). Low testosterone reduces anabolic capacity for nerve and vascular repair. The structural damage from the metabolic-inflammatory cascade cannot be repaired because the hormonal environment required for repair is itself dysfunctional. Gabapentinoids often cause somnolence and cognitive impairment that paradoxically worsen functional sleep quality despite increasing total sleep time. Pregabalin-induced weight gain worsens the metabolic cascade that is driving the neuropathy.

5.4 The Gut-Immune-Nerve Cascade

Gut barrier dysfunction (Camilleri, 2019) produces systemic LPS translocation and NF-κB-mediated inflammation. This systemic inflammatory tone activates spinal cord glial cells, promoting central sensitization (Watkins and Maier, 2002; Woolf, 2011). The resulting pain amplification causes a patient with moderate nerve compression or mild neuropathy to experience severe symptoms because the nervous system is already primed by systemic inflammation. Gut dysbiosis reduces serotonin production, weakening descending pain inhibition. Gastrointestinal side effects from duloxetine and gabapentinoids may worsen gut barrier function, potentially accelerating this cascade in treated patients.

6. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention for leg pain. All laboratory values represent plausible clinical findings consistent with the domain dysfunction documented in the cited studies.

6.1 Patient A: Metabolic-Neuropathic Pattern

Presentation: 58-year-old man, BMI 34, with bilateral burning and tingling in both feet progressing to below the knees over 3 years. HbA1c 6.4% (prediabetic). Nerve conduction studies show mild sensorimotor polyneuropathy. Gabapentin 1800 mg daily provides approximately 30% pain reduction. Reports numbness, balance difficulty, and nonrestorative sleep. Pain 6/10.

Domain Assessment — Laboratory Findings: Fasting insulin 22 µIU/mL (elevated; reference <10), HOMA-IR 5.6 (elevated), triglycerides 228 mg/dL, HDL 36 mg/dL. hs-CRP 4.2 mg/L (elevated). Vitamin D 18 ng/mL (deficient). Omega-3 index 2.6% (critically low). RBC magnesium low. B12 380 pg/mL (low-normal with elevated methylmalonic acid confirming functional insufficiency). Heavy metal screen showing lead 4.8 µg/dL (elevated). Organic acids showing markers consistent with mitochondrial dysfunction.

Domain Interpretation: This patient demonstrates the metabolic nerve vulnerability cascade. Significant insulin resistance is damaging the vasa nervorum through endothelial dysfunction, creating chronic nerve ischemia. Elevated lead represents a detoxification domain burden with direct neurotoxic effects. Functional B12 insufficiency impairs methylation and myelin maintenance. The prediabetic metabolic profile combined with severely deficient vitamin D, critically low omega-3 index, and elevated inflammatory markers creates a hostile metabolic environment for nerve survival and repair. Gabapentin provides partial calcium-channel modulation without addressing any upstream driver.

Individualized Protocol: Metabolic optimization targeting insulin sensitization through anti-inflammatory dietary protocol and graded exercise. Lead burden reduction with glutathione support (IV glutathione 600–1200 mg one to two times weekly). B12 repletion (methylcobalamin form). Vitamin D repletion to 50–80 ng/mL. Omega-3 repletion to index >8%. Magnesium repletion. MOTS-c (5–10 mg SC three times weekly, morning) targeting AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). BPC-157 (250–500 µg orally twice daily) for nitric oxide restoration and gut barrier support (Gwyer et al., Cell and Tissue Research, 2019). ARA-290 (2 mg SC three times weekly) targeting the innate repair receptor for nerve fiber repair, based on Phase II data showing increased corneal nerve fiber density and reduced neuropathic symptoms in patients with small fiber neuropathy (Heij et al., Molecular Medicine, 2012; Culver et al., IOVS, 2017). GHK-Cu (1–2 mg SC daily) for nerve outgrowth stimulation and gene expression modulation toward repair (Pickart et al., International Journal of Molecular Sciences, 2018). Reassessment of metabolic markers, nerve conduction studies, and inflammatory markers at 6 months.

6.2 Patient B: Vascular-Metabolic-Inflammatory Pattern

Presentation: 66-year-old man, former smoker (30 pack-years, quit 5 years ago), with bilateral calf pain after walking two blocks that resolves with rest. ABI 0.62 bilateral. Also reports nighttime leg heaviness, ankle swelling, and skin darkening at the ankles. Duplex ultrasound shows moderate bilateral superficial femoral artery stenosis and great saphenous vein reflux. Currently taking aspirin, atorvastatin, and cilostazol. Pain limits walking to 200 meters.

Domain Assessment — Laboratory Findings: Fasting insulin 18 µIU/mL (elevated), HbA1c 6.0% (prediabetic). hs-CRP 5.4 mg/L (elevated). Homocysteine 16 µmol/L (elevated). Fibrinogen elevated. Total testosterone 245 ng/dL (low). DHEA-S markedly low. Vitamin D 21 ng/mL (deficient). Omega-3 index 3.2% (critically low). D-dimer mildly elevated.

Domain Interpretation: This patient demonstrates the vascular-metabolic-inflammatory cascade with dual vascular pathology. Arterial insufficiency and venous insufficiency coexist, a combination frequently missed when patients are evaluated by separate specialists. Insulin resistance is driving endothelial dysfunction in both arterial and venous beds. Elevated homocysteine indicates methylation pathway dysfunction contributing to vascular damage. Low testosterone and DHEA-S represent hormonal insufficiency impairing vascular repair capacity. The inflammatory markers confirm systemic inflammation feeding atherogenesis and venous wall damage. Cilostazol provides modest vasodilation without addressing the metabolic syndrome or endothelial dysfunction driving disease progression.

Individualized Protocol: Metabolic optimization targeting insulin resistance and endothelial function restoration. Supervised exercise program. Venous evaluation for possible ablation of refluxing saphenous vein (addressing venous component). Testosterone and DHEA optimization guided by endocrine assessment. Homocysteine reduction through methylfolate and B-vitamin optimization. Vitamin D repletion. Omega-3 repletion. MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., 2015). BPC-157 (250–500 µg SC twice daily) for nitric oxide restoration and endothelial repair (Gwyer et al., 2019). SS-31 (5–10 mg SC daily) for mitochondrial membrane stabilization in ischemic skeletal muscle (Szeto, British Journal of Pharmacology, 2014; Birk et al., JASN, 2013). Ipamorelin/CJC-1295 at bedtime for growth hormone restoration supporting vascular repair. Reassessment of metabolic, inflammatory, and vascular markers at 6 months.

6.3 Patient C: Radicular-Inflammatory-Neuroendocrine Pattern

Presentation: 44-year-old woman with 18-month history of left leg pain radiating from buttock to lateral calf. MRI shows L5-S1 disc protrusion with mild left foraminal narrowing. Two epidural steroid injections provided 4–6 weeks of relief each. Reports anxiety, poor sleep, food sensitivities, and fatigue. Pain 7/10 with allodynia along the lateral thigh. Physical therapy has provided limited improvement.

Domain Assessment — Laboratory Findings: Fasting insulin 8 µIU/mL (normal). HbA1c 5.2% (normal). hs-CRP 3.1 mg/L (mildly elevated). Elevated evening cortisol (loss of normal diurnal decline). Positive SIBO breath test. Elevated zonulin (intestinal permeability marker). Microbiome analysis showing reduced diversity. Vitamin D 26 ng/mL (suboptimal). Vitamin B12 normal. Hormonal panel otherwise unremarkable.

Domain Interpretation: This patient demonstrates the gut-immune-sensitization cascade producing persistent radiculopathy disproportionate to imaging findings. Normal metabolic markers exclude insulin resistance as the primary driver. The allodynia suggests central sensitization (Woolf, 2011). Positive SIBO and elevated zonulin confirm gut barrier dysfunction feeding systemic inflammation through LPS translocation (Camilleri, 2019). Elevated evening cortisol reflects HPA axis overactivation. The structural finding — mild foraminal narrowing — would likely be tolerated in a patient without systemic inflammatory priming. But this patient’s nerve root is sensitized by gut-derived systemic inflammation and central sensitization, making even mild compression symptomatic. Each epidural injection temporarily suppressed local inflammation without addressing the upstream gut-immune cascade.

Individualized Protocol: SIBO treatment per established protocols. Oral BPC-157 (250–500 µg twice daily) for gut barrier restoration (Gwyer et al., 2019). KPV (200–400 µg orally twice daily) targeting NF-κB inhibition at the gut mucosal level. Elimination dietary protocol. Selank (250–500 µg SC two to three times daily) for anxiety and HPA axis modulation without sedation or GI side effects (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008). DSIP (100–200 µg SC at bedtime) for deep sleep restoration and growth hormone release. Vitamin D optimization. Continued physical therapy with graded exposure approach for central sensitization. Reassessment of SIBO, intestinal permeability, inflammatory markers, and cortisol curve at 12 weeks.

7. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer the potential for domain-targeted intervention in leg pain. Unlike single-mechanism pharmaceuticals, peptides interact with biological signaling pathways that may address domain-level dysfunction. The following peptides have published evidence connecting their mechanisms to biological domains documented as dysfunctional in leg pain conditions. No large-scale randomized controlled trials of these peptides for leg pain as a primary indication have been published; evidence is extrapolated from mechanism-of-action studies and trials in related conditions.

ARA-290 (cibinetide) activates the innate repair receptor (IRR), a receptor complex involving the erythropoietin receptor and IL-3 receptor beta chain, promoting tissue repair and reducing inflammation without stimulating red blood cell production. ARA-290 has the most advanced clinical evidence of any peptide for neuropathic pain. In a Phase II randomized, double-blind, placebo-controlled trial of 22 sarcoidosis patients with small fiber neuropathy, ARA-290 significantly reduced pain scores and neuropathic symptoms (Heij et al., Molecular Medicine, 2012). A subsequent Phase II study in patients with type 2 diabetes demonstrated improvement in HbA1c, neuropathic symptoms, and corneal nerve fiber density (Brines et al., Molecular Medicine, 2014). A Phase 2b trial in 64 patients with sarcoidosis-associated neuropathy demonstrated significant nerve fiber regeneration as measured by corneal confocal microscopy and reductions in neuropathic pain (Culver et al., Investigative Ophthalmology and Visual Science, 2017). ARA-290 has received Orphan Drug and Fast Track designations from the FDA. Administered subcutaneously at 2 mg three times weekly. Not FDA-approved for general neuropathy indications.

BPC-157 has demonstrated nerve regeneration in preclinical models of sciatic nerve transection, with faster axonal regeneration, improved myelination, and functional recovery (Gjurasin et al., Regulatory Peptides, 2010). Additional evidence supports spinal cord injury recovery (Perovic et al., Journal of Orthopaedic Surgery and Research, 2019) and broad anti-inflammatory, angiogenic, and tissue-repair properties (Gwyer et al., Cell and Tissue Research, 2019). BPC-157 restores nitric oxide production in blood vessel walls, directly targeting endothelial dysfunction relevant to both neuropathic and vascular leg pain. Oral 250–500 µg twice daily or subcutaneous injection near the site of nerve injury. Not FDA-approved.

MOTS-c activates AMPK (adenosine monophosphate-activated protein kinase), a master energy-sensing switch that improves insulin sensitivity, reduces inflammatory cytokines, and promotes metabolic homeostasis (Lee et al., Cell Metabolism, 2015). MOTS-c production increases approximately twelve-fold in skeletal muscle during exercise. Its relevance to leg pain is the direct targeting of insulin resistance — the metabolic driver of nerve vulnerability, vascular disease, and disc degeneration documented throughout this review. Subcutaneously at 5–10 mg three times weekly in the morning. Not FDA-approved.

GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production, promotes nerve outgrowth, and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, BioMed Research International, 2014; Pickart et al., International Journal of Molecular Sciences, 2018). Its nerve outgrowth promotion is directly relevant to peripheral neuropathy and small fiber neuropathy. Subcutaneously 1–2 mg daily. Not FDA-approved.

SS-31 (elamipretide) selectively targets the inner mitochondrial membrane by binding cardiolipin, stabilizing electron transport chain organization and improving bioenergetic efficiency (Szeto, British Journal of Pharmacology, 2014; Birk et al., JASN, 2013). Clinical trials have been completed in primary mitochondrial myopathy (Karaa et al., Neurology, 2018). Its relevance to leg pain includes supporting mitochondrial function in ischemic skeletal muscle in PAD and in metabolically stressed nerve tissue. Subcutaneously at 5–10 mg daily. Not FDA-approved for pain indications.

TB-500 promotes cell migration to injured tissue and anti-fibrotic tissue remodeling (Malinda et al., Journal of Investigative Dermatology, 1999). Relevant for nerve and vascular tissue repair. Subcutaneously 750 µg to 1.5 mg twice weekly. Not FDA-approved.

Peptide protocols are individualized based on domain assessment findings. The clinical scenarios in Section 6 illustrate how peptide selection is directed by laboratory data rather than applied as a standardized protocol. Additional peptides targeting immune regulation, detoxification, hormonal restoration, and sleep architecture may be indicated based on individual assessment.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, chronic leg pain — whether presenting as radiculopathy, peripheral neuropathy, vascular claudication, chronic venous insufficiency, or neurogenic claudication — involves measurable dysfunction across multiple biological domains, not merely isolated structural or vascular pathology. Insulin resistance, systemic inflammation, endothelial dysfunction, hormonal insufficiency, gut barrier dysfunction, and oxidative stress have each been independently documented in association with the conditions that cause chronic leg pain.

Second, the limited, partial, short-term response to single-pathway treatments is consistent with a multi-domain disorder. When gabapentinoids have NNTs of 5–10, when epidural injections show short-term but not long-term benefit, and when cilostazol adds only 40 meters to claudication walking distance, the data are not showing that these interventions are ineffective. They are showing that these interventions address only one component of a multi-component problem. The near-universal prevalence of disc degeneration in asymptomatic populations (Brinjikji et al., 2015) further demonstrates that structural pathology alone cannot explain who develops radicular leg pain. The concept of metabolic nerve vulnerability explains the variability in treatment response: a nerve in a healthy metabolic environment can tolerate mechanical stress that a metabolically compromised nerve cannot.

Third, conventional treatments can actively worsen domains they do not target. Pregabalin causes weight gain that worsens insulin resistance. Gabapentinoids cause edema and somnolence that impair physical activity. Duloxetine causes gastrointestinal effects that may worsen gut barrier function. Opioids suppress the HPA axis, reduce testosterone, disrupt sleep, and cause weight gain. These destabilizing effects help explain why chronic leg pain is often a progressive condition despite ongoing treatment.

Cellular systems theory does not dismiss structural-mechanical or vascular diagnosis or treatment. Structural findings are real, vascular disease is real, and interventional procedures provide essential acute relief. The theory proposes that these findings represent the visible consequence of upstream biological dysfunction, and that durable improvement requires addressing both the structural or vascular damage and the biological environment that produced it.

Limitations include the narrative methodology, the observational nature of key metabolic studies, the preclinical basis of most peptide evidence (with the exception of ARA-290’s Phase II human data), and the absence of randomized controlled trials testing multi-domain interventions in leg pain populations. The clinical scenarios are composite illustrations, not case reports from controlled studies. Prospective trials comparing individualized domain-targeted protocols with standard care are needed.

9. Conclusion

Chronic leg pain is treated through separate diagnostic and therapeutic silos — the neurologist manages the neuropathy, the vascular surgeon manages the claudication, the interventional pain physician manages the radiculopathy — yet the published evidence demonstrates shared upstream biological dysfunction across metabolic, inflammatory, vascular, hormonal, and microbiome domains. Cellular systems theory provides a unifying framework for understanding why the nerve became vulnerable, why the artery became stenotic, why the disc herniation became symptomatic, and why conventional treatments provide temporary or partial relief. By identifying and addressing the biological domains driving the condition in each individual patient, cellular systems analysis offers a path toward more durable outcomes. Emerging peptide therapeutics targeting metabolic, mitochondrial, inflammatory, neuroprotective, and tissue repair pathways — particularly ARA-290, which has demonstrated nerve fiber regeneration in human clinical trials — warrant prospective clinical investigation in leg pain populations.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. Konstantinou K, Dunn KM. Sciatica: review of epidemiological studies and prevalence estimates. Spine. 2008;33(22):2464-2472.

2. Criqui MH, Matsushita K, Aboyans V, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions. Circulation. 2021;144(9):e171-e191.

3. Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Revue Neurologique. 2019;175(1-2):16-25.

4. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;130(4):333-346.

5. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2017;6:CD007938.

6. AAN Guidelines Subcommittee. Epidural steroids for radicular pain and spinal stenosis: systematic review summary. Neurology. 2025;104(6):e210258.

7. Brown T, Forster RB, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews. 2021;6:CD003748.

8. Que Z, Chen D, Cai H, et al. Insulin resistance and low back pain in US adults. Frontiers in Medicine. 2025;12:1538754.

9. Guo W, Li BL, Zhao JY, et al. Causal associations between modifiable risk factors and intervertebral disc degeneration. Spine Journal. 2024;24(2):195-209.

10. Garg PK, Biggs ML, Carnethon M, et al. Metabolic syndrome and risk of incident peripheral artery disease. Hypertension. 2014;63(2):413-419.

11. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in cauda equina nerve roots. Spine. 1993;18(11):1425-1432.

12. Zhai X, Sun C, Rong P, et al. Chronic pain and insulin resistance. Journal of Pain. 2016;17:404-413.

13. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal. 2008;22(10):3432-3442.

14. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

15. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiological Reviews. 2002;82(4):981-1011.

16. Finan PH, Goodin BR, Smith MT. Sleep and pain association. Journal of Pain. 2013;14(12):1539-1552.

17. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology. 2015;11(9):513-520.

18. Heim C, Ehlert U, Hellhammer DH. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

19. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

20. Minerbi A, et al. Altered microbiome in fibromyalgia. Pain. 2019;160(11):2589-2602.

21. Erdrich S, et al. Fibromyalgia and SIBO. Clinical and Experimental Rheumatology. 2020;38(Suppl 123):165-175.

22. Brinjikji W, Luetmer PH, Comstock B, et al. Systematic review of imaging features of spinal degeneration in asymptomatic populations. AJNR. 2015;36(4):811-816.

23. Uceyler N, et al. Small fibre pathology in fibromyalgia. Brain. 2013;136(Pt 6):1857-1867.

24. Albrecht PJ, et al. Excessive sensory innervation of cutaneous AVS in fibromyalgia. Pain Medicine. 2013;14(6):895-915.

25. Lin J, et al. Chronic venous insufficiency and pain. World Journal of Clinical Cases. 2024.

26. Peul WC, van Houwelingen HC, van den Hout WB, et al. Surgery versus prolonged conservative treatment for sciatica. New England Journal of Medicine. 2007;356(22):2245-2256.

27. Liu C, Ferreira GE, Abdel Shaheed C, et al. Surgical versus non-surgical treatment for sciatica. BMJ. 2023;381:e070730.

28. Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2019;1:CD007076.

29. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia. Pain. 2008;137(2):320-329.

30. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review and meta-analysis. Lancet Neurology. 2015;14(2):162-173.

31. Fakhry F, van de Weg EM, Rouwet EV, et al. Supervised walking therapy for intermittent claudication. JAMA. 2012;308(14):1471-1480.

32. Bicket MC, Gupta A, Brown CH, Cohen SP. Epidural injections for spinal pain: meta-analysis. Anesthesiology. 2013;119(4):907-931.

33. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015;21(3):443-454.

34. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Molecular Medicine. 2012;18:1430-1436.

35. Brines M, Dunne AN, van Velzen M, et al. ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2014;20:658-666.

36. Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in sarcoidosis-associated small nerve fiber loss. Investigative Ophthalmology and Visual Science. 2017;58(6):BIO52-BIO60.

37. Gjurasin M, et al. BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1-3):33-41.

38. Perovic D, et al. BPC 157 in spinal cord injury. Journal of Orthopaedic Surgery and Research. 2019;14(1):199.

39. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research. 2019;377(2):153-159.

40. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed Research International. 2014;2014:151479.

41. Pickart L, et al. GHK-Cu regenerative actions. International Journal of Molecular Sciences. 2018;19(7):1987.

42. Szeto HH. Cardiolipin-protective compound for mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.

43. Birk AV, et al. SS-31 re-energizes mitochondria via cardiolipin. JASN. 2013;24(8):1250-1261.

44. Karaa A, et al. Elamipretide trial in mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.

45. Malinda KM, et al. Thymosin beta4 in wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368.

46. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

47. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration. Nature Reviews Rheumatology. 2014;10(1):44-56.

48. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain. Pain. 1999;83(3):389-400.

49. Teraguchi M, et al. Metabolic syndrome and disc degeneration: the Wakayama Spine Study. PLoS One. 2016;11(2):e0147565.

50. Helde-Frankling M, Bjorkhem-Bergman L. Vitamin D in pain management. IJMS. 2017;18(10):2170.

© 2026 Alabama Pain Physicians. All rights reserved.